Artiva Biotherapeutics Inc.

Plus: C-suite changes at Freenome, Telix, Trex Bio, Myricx, General Oncology, Bostongene and Acrivon

$167M raise by NK cell therapy company highlight of slow week for public equity

Plus: Artiva takes second look at IPO, Moderna gets $176M BARDA award

Plus: Peter Flynn at the helm at Arialys, and updates from Augustine, CND, Parallel Bio and Zevra

Plus: At last, approval Ipsen FOP therapy Sohono and updates from Compass Pathways, Day One-Sprint, Seagen, Artiva, Precision-Imugene, Impel

Among dozens of companies that raised crossover cash before markets turned sour, some may soon have what it takes to go public

Fate’s pipeline reprioritization raises questions about iPSC-derived NK cells

Meeting highlights new platforms combining pieces of cell therapy, bispecific, oncolytic virus and cytokine peptide technologies

Plus Vicore gains on IPF data and updates from Acrivon, BioAtla, Novadip and more

Plus NextCure abandons SIGLEC15 and updates from Emalex, Moderna, Aurinia, Affimed, Artiva and more